The Lancet - McMaster Experts

publication venue for

Reduced ability to engage in social and physical activity and mental health of older adults during the COVID-19 pandemic: longitudinal analysis from the Canadian Longitudinal Study on Aging 2021
Understanding the impact of a new public health approach to end-of-life care: a qualitative study of a community led intervention 2017
Coordination of health-service provision in humanitarian crises: a systematic review of suggested models 2017
Establishing disability weights for congenital paediatric surgical disease: a cross-sectional, multi-modal study 2013
Equitable access to pandemic products demands stronger public governance.. 404:2030-2032. 2024
Global, regional, and national stillbirths at 20 weeks' gestation or longer in 204 countries and territories, 1990-2021: findings from the Global Burden of Disease Study 2021.. 404:1955-1988. 2024
National-level and state-level prevalence of overweight and obesity among children, adolescents, and adults in the USA, 1990-2021, and forecasts up to 2050.. S0140-6736(24)01548-4. 2024
Optimal timing of anticoagulation after acute ischaemic stroke with atrial fibrillation (OPTIMAS): a multicentre, blinded-endpoint, phase 4, randomised controlled trial.. 404:S0140-6736(24)02197-4. 2024
Global burden of bacterial antimicrobial resistance 1990-2021: a systematic analysis with forecasts to 2050.. 404:1199-1226. 2024
Antivirals for post-exposure prophylaxis of influenza: a systematic review and network meta-analysis.. 404:764-772. 2024
Antivirals for treatment of severe influenza: a systematic review and network meta-analysis of randomised controlled trials.. 404:753-763. 2024
Activity limitations, use of assistive devices, and mortality and clinical events in 25 high-income, middle-income, and low-income countries: an analysis of the PURE study. 404:554-569. 2024
Counting the dead in Gaza: difficult but essential. 404:237-238. 2024
Long-term colchicine for the prevention of vascular recurrent events in non-cardioembolic stroke (CONVINCE): a randomised controlled trial. 404:125-133. 2024
Adding 6 months of androgen deprivation therapy to postoperative radiotherapy for prostate cancer: a comparison of short-course versus no androgen deprivation therapy in the RADICALS-HD randomised controlled trial. 403:2405-2415. 2024
Ductal carcinoma in situ of the breast: finding the balance between overtreatment and undertreatment. 403:2734-2746. 2024
Duration of androgen deprivation therapy with postoperative radiotherapy for prostate cancer: a comparison of long-course versus short-course androgen deprivation therapy in the RADICALS-HD randomised trial. 403:2416-2425. 2024
Tenecteplase versus standard of care for minor ischaemic stroke with proven occlusion (TEMPO-2): a randomised, open label, phase 3 superiority trial. 403:2597-2605. 2024
Burden of disease scenarios for 204 countries and territories, 2022–2050: a forecasting analysis for the Global Burden of Disease Study 2021. 403:2204-2256. 2024
Global age-sex-specific mortality, life expectancy, and population estimates in 204 countries and territories and 811 subnational locations, 1950–2021, and the impact of the COVID-19 pandemic: a comprehensive demographic analysis for the Global Burden of Disease Study 2021. 403:1989-2056. 2024
Global burden and strength of evidence for 88 risk factors in 204 countries and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021. 403:2162-2203. 2024
Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021. 403:2100-2132. 2024
Global fertility in 204 countries and territories, 1950–2021, with forecasts to 2100: a comprehensive demographic analysis for the Global Burden of Disease Study 2021. 403:2057-2099. 2024
Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021. 403:2133-2161. 2024
Pharmacotherapy for adults with overweight and obesity: a systematic review and network meta-analysis of randomised controlled trials. 403:e21-e31. 2024
Prioritising actions to address stagnating maternal mortality rates globally. 403:417-419. 2024
Pembrolizumab plus chemotherapy versus chemotherapy in untreated advanced pleural mesothelioma in Canada, Italy, and France: a phase 3, open-label, randomised controlled trial. 402:2295-2306. 2023
Effect of colchicine on perioperative atrial fibrillation and myocardial injury after non-cardiac surgery in patients undergoing major thoracic surgery (COP-AF): an international randomised trial. 402:1627-1635. 2023
Effective and safe regional node irradiation in early breast cancer. 402:1943-1945. 2023
Inhibition of neonatal Fc receptor as a treatment for immune thrombocytopenia. 402:1599-1601. 2023
Malnutrition in older adults: a wider view. 402:1976-1976. 2023
The Lancet Commission on peaceful societies through health equity and gender equality. 402:1661-1722. 2023
Anticoagulation in patients with cerebral amyloid angiopathy. 402:1418-1419. 2023
Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021. 402:203-234. 2023
Self-administered intranasal etripamil using a symptom-prompted, repeat-dose regimen for atrioventricular-nodal-dependent supraventricular tachycardia (RAPID): a multicentre, randomised trial. 402:118-128. 2023
Cognitive functional therapy for chronic disabling low back pain.. 401:1828-1829. 2023
Latent bipolar disorder. 401:2109-2109. 2023
Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial. 401:1853-1865. 2023
Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study. 401:269-280. 2023
Global mortality associated with 33 bacterial pathogens in 2019: a systematic analysis for the Global Burden of Disease Study 2019. 400:2221-2248. 2022
Revisiting RECORD4. 400:2047-2048. 2022
WHO Living Guidelines on antivirals for COVID-19 are evidence-based. 400:2196-2198. 2022
Personalised cooler dialysate for patients receiving maintenance haemodialysis (MyTEMP): a pragmatic, cluster-randomised trial. 400:1693-1703. 2022
The polypill: from concept and evidence to implementation. 400:1661-1663. 2022
Aqueous skin antisepsis before surgical fixation of open fractures (Aqueous-PREP): a multiple-period, cluster-randomised, crossover trial. 400:1334-1344. 2022
Suture choice for cervical cerclage. 400:1385-1387. 2022
Effect of statin therapy on muscle symptoms: an individual participant data meta-analysis of large-scale, randomised, double-blind trials. 400:832-845. 2022
Factor XIa inhibition with asundexian after acute non-cardioembolic ischaemic stroke (PACIFIC-Stroke): an international, randomised, double-blind, placebo-controlled, phase 2b trial. 400:997-1007. 2022
Global, regional, and national burden of hepatitis B, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. 7:796-829. 2022
Metabolic, behavioural, and psychosocial risk factors and cardiovascular disease in women compared with men in 21 high-income, middle-income, and low-income countries: an analysis of the PURE study. 400:811-821. 2022
Radiation doses and fractionation schedules in non-low-risk ductal carcinoma in situ in the breast (BIG 3–07/TROG 07.01): a randomised, factorial, multicentre, open-label, phase 3 study. 400:431-440. 2022
The global burden of cancer attributable to risk factors, 2010–19: a systematic analysis for the Global Burden of Disease Study 2019. 400:563-591. 2022
WHO must live up to its values and include data on Palestinians. 400:427-427. 2022
Intravenous tenecteplase compared with alteplase for acute ischaemic stroke in Canada (AcT): a pragmatic, multicentre, open-label, registry-linked, randomised, controlled, non-inferiority trial. 400:161-169. 2022
Viral hepatitis elimination: a challenge, but within reach. 400:251-251. 2022
Coeliac disease. 399:2413-2426. 2022
Measuring the availability of human resources for health and its relationship to universal health coverage for 204 countries and territories from 1990 to 2019: a systematic analysis for the Global Burden of Disease Study 2019. 399:2129-2154. 2022
Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial. 399:2200-2211. 2022
Aggressive intraoperative warming versus routine thermal management during non-cardiac surgery (PROTECT): a multicentre, parallel group, superiority trial. 399:1799-1808. 2022
Challenging dogma about perioperative warming during non-cardiac surgery. 399:1757-1759. 2022
The addition of androgen deprivation therapy and pelvic lymph node treatment to prostate bed salvage radiotherapy (NRG Oncology/RTOG 0534 SPPORT): an international, multicentre, randomised phase 3 trial. 399:1886-1901. 2022
A call for an immediate ceasefire and peaceful end to the Russian aggression against Ukraine. 399:1284-1287. 2022
Disease-modifying anti-asthmatic drugs. 399:1664-1668. 2022
Reduction of dietary sodium to less than 100 mmol in heart failure (SODIUM-HF): an international, open-label, randomised, controlled trial. 399:1391-1400. 2022
Evaluating COVID-19 vaccines in the real world. 399:1205-1206. 2022
Prophylactic use of an anti-activated factor XII monoclonal antibody, garadacimab, for patients with C1-esterase inhibitor-deficient hereditary angioedema: a randomised, double-blind, placebo-controlled, phase 2 trial. 399:945-955. 2022
Governing the Access to COVID-19 Tools Accelerator: towards greater participation, transparency, and accountability. 399:487-494. 2022
Pharmacotherapy for adults with overweight and obesity: a systematic review and network meta-analysis of randomised controlled trials. 399:259-269. 2022
Racialised people in clinical guideline panels. 399:139-140. 2022
The Lancet Commission on the future of care and clinical research in autism. 399:271-334. 2022
COV-BOOST: evidence to support rapid booster deployment Comment. 398:2209-2211. 2021
PCI versus CABG for left main coronary artery disease: is the jury still out?. 398:2208-2209. 2021
Blood pressure lowering and risk of new-onset type 2 diabetes: an individual participant data meta-analysis. 398:1803-1810. 2021
Global, regional, and national mortality among young people aged 10–24 years, 1950–2019: a systematic analysis for the Global Burden of Disease Study 2019. 398:1593-1618. 2021
Tracking development assistance for health and for COVID-19: a review of development assistance, government, out-of-pocket, and other private spending on health for 204 countries and territories, 1990–2050. 398:1317-1343. 2021
Age-stratified and blood-pressure-stratified effects of blood-pressure-lowering pharmacotherapy for the prevention of cardiovascular disease and death: an individual participant-level data meta-analysis. 398:1053-1064. 2021
Fixed-dose combination therapies with and without aspirin for primary prevention of cardiovascular disease: an individual participant data meta-analysis. 398:1133-1146. 2021
The use of inhaled corticosteroids in early-stage COVID-19. 398:818-819. 2021
Measuring routine childhood vaccination coverage in 204 countries and territories, 1980–2019: a systematic analysis for the Global Burden of Disease Study 2020, Release 1. 398:503-521. 2021
Revisiting the evidence for physical distancing, face masks, and eye protection – Authors' reply. 398:663-664. 2021
WHO COVID-19 therapeutic guidelines. 398:117-118. 2021
Spatial, temporal, and demographic patterns in prevalence of smoking tobacco use and attributable disease burden in 204 countries and territories, 1990–2019: a systematic analysis from the Global Burden of Disease Study 2019. 397:2337-2360. 2021
Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis. 397:1625-1636. 2021
Priorities for COVID-19 research response and preparedness in low-resource settings. 397:1866-1868. 2021
Associations of urinary sodium excretion with cardiovascular events in individuals with and without hypertension: a pooled analysis of data from four studies (vol 388, pg 465, 2016). 397:1350-1350. 2021
Hearing loss prevalence and years lived with disability, 1990–2019: findings from the Global Burden of Disease Study 2019. 397:996-1009. 2021
How low can we go in community-acquired pneumonia therapy?. 397:1160-1161. 2021
Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial. 397:475-486. 2021
COVID-19 vaccines for Palestinians. 397:579-579. 2021
Posaconazole versus voriconazole for primary treatment of invasive aspergillosis: a phase 3, randomised, controlled, non-inferiority trial. 397:499-509. 2021
Public policy and health in the Trump era. 397:705-753. 2021
Recognising HIV infection in systems of care for stroke – Authors' reply. 397:794-795. 2021
Transdermal oestradiol for androgen suppression in prostate cancer: long-term cardiovascular outcomes from the randomised Prostate Adenocarcinoma Transcutaneous Hormone (PATCH) trial programme. 397:581-591. 2021
Causal ordering among risk factors in the PURE study – Authors' reply. 397:279-279. 2021
Global variation in postoperative mortality and complications after cancer surgery: a multicentre, prospective cohort study in 82 countries. 397:387-397. 2021
Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial. 396:1895-1904. 2020
Direct oral anticoagulants: evidence and unresolved issues. 396:1767-1776. 2020
Emergency use authorisation for COVID-19 vaccines: lessons from Ebola. 396:1707-1709. 2020
Surgery during the COVID-19 pandemic. 396:e74-e74. 2020
Accelerated surgery for hip fractures—the HIP ATTACK results discussed – Authors' reply. 396:1332-1332. 2020
Five insights from the Global Burden of Disease Study 2019. 396:1135-1159. 2020
Global age-sex-specific fertility, mortality, healthy life expectancy (HALE), and population estimates in 204 countries and territories, 1950–2019: a comprehensive demographic analysis for the Global Burden of Disease Study 2019. 396:1160-1203. 2020
Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. 396:1204-1222. 2020
Global burden of 87 risk factors in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. 396:1223-1249. 2020
Measuring universal health coverage based on an index of effective coverage of health services in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. 396:1250-1284. 2020
Plasma ACE2 and risk of death or cardiometabolic diseases: a case-cohort analysis. 396:968-976. 2020
Stroke systems of care in low-income and middle-income countries: challenges and opportunities. 396:1443-1451. 2020
Health sector spending and spending on HIV/AIDS, tuberculosis, and malaria, and development assistance for health: progress towards Sustainable Development Goal 3. 396:693-724. 2020
After COVID-19, a future for the world's children?. 396:298-300. 2020
Cardiovascular risk in hypertension: open questions about HOPE 4 – Authors' reply. 396:310-311. 2020
Solidarity in the wake of COVID-19: reimagining the International Health Regulations. 396:82-83. 2020
Variations between women and men in risk factors, treatments, cardiovascular disease incidence, and death in 27 high-income, middle-income, and low-income countries (PURE): a prospective cohort study. 396:97-109. 2020
Mapping geographical inequalities in childhood diarrhoeal morbidity and mortality in low-income and middle-income countries, 2000-17: analysis for the Global Burden of Disease Study 2017 (vol 395, pg 1779, 2020). 395:1762-1762. 2020
Department of Error. 395:1762-1762. 2020
Effects of a high-dose 24-h infusion of tranexamic acid on death and thromboembolic events in patients with acute gastrointestinal bleeding (HALT-IT): an international randomised, double-blind, placebo-controlled trial. 395:1927-1936. 2020
Mapping geographical inequalities in childhood diarrhoeal morbidity and mortality in low-income and middle-income countries, 2000–17: analysis for the Global Burden of Disease Study 2017. 395:1779-1801. 2020
Physical distancing, face masks, and eye protection to prevent person-to-person transmission of SARS-CoV-2 and COVID-19: a systematic review and meta-analysis. 395:1973-1987. 2020
What does it mean to be made vulnerable in the era of COVID-19? (vol 395, pg 1481, 2020). 395:1486-1486. 2020
What does it mean to be made vulnerable in the era of COVID-19?. 395:1481-1482. 2020
Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke (ESCAPE-NA1): a multicentre, double-blind, randomised controlled trial. 395:878-887. 2020
Modifiable risk factors, cardiovascular disease, and mortality in 155 722 individuals from 21 high-income, middle-income, and low-income countries (PURE): a prospective cohort study. 395:795-808. 2020
Variations in common diseases, hospital admissions, and deaths in middle-aged adults in 21 countries from five continents (PURE): a prospective cohort study. 395:785-794. 2020
A future for the world's children? A WHO–UNICEF–Lancet Commission. 395:605-658. 2020
Do not violate the International Health Regulations during the COVID-19 outbreak. 395:664-666. 2020
Dulaglutide slows kidney disease in type 2 diabetes − Author's reply. 395:559-560. 2020
Global, regional, and national burden of chronic kidney disease, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. 395:709-733. 2020
Perception of severity of adverse events in oral immunotherapy – Authors' reply. 395:415-416. 2020
Accelerated surgery versus standard care in hip fracture (HIP ATTACK): an international, randomised, controlled trial. 395:698-708. 2020
External beam accelerated partial breast irradiation versus whole breast irradiation after breast conserving surgery in women with ductal carcinoma in situ and node-negative breast cancer (RAPID): a randomised controlled trial. 394:2165-2172. 2019
A roadmap for sustainably governing the global antimicrobial commons. 394:1788-1789. 2019
A community-based comprehensive intervention to reduce cardiovascular risk in hypertension (HOPE 4): a cluster-randomised controlled trial. 394:1231-1242. 2019
Prediction of mortality benefit based on periodic repolarisation dynamics in patients undergoing prophylactic implantation of a defibrillator: a prospective, controlled, multicentre cohort study. 394:1344-1351. 2019
Perioperative covert stroke in patients undergoing non-cardiac surgery (NeuroVISION): a prospective cohort study. 394:1022-1029. 2019
Planned early delivery or expectant management for late preterm pre-eclampsia (PHOENIX): a randomised controlled trial. 394:1181-1190. 2019
Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial. 394:1169-1180. 2019
The evolution of fractionated prostate cancer radiotherapy. 394:361-362. 2019
The importance of randomised vs non-randomised trials – Authors' reply. 394:635-635. 2019
Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. 394:121-130. 2019
Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial. 394:131-138. 2019
Department of Error. 393:e44-e44. 2019
Oral immunotherapy for peanut allergy (PACE): a systematic review and meta-analysis of efficacy and safety. 393:2222-2232. 2019
Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial. 393:1937-1947. 2019
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. 393:1819-1830. 2019
Urinary sodium excretion measures and health outcomes-Authors' reply (vol 393, pg 1295, 2019). 393:1596-1596. 2019
Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials. 393:1440-1452. 2019
Urinary sodium excretion measures and health outcomes – Authors' reply. 393:1295-1296. 2019
Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials. 393:407-415. 2019
Gender bias in academia. 393:741-743. 2019
Time for gender-transformative change in the health workforce. 393:e25-e26. 2019
Effects of fluoxetine on functional outcomes after acute stroke (FOCUS): a pragmatic, double-blind, randomised, controlled trial. 393:265-274. 2019
Real-world studies no substitute for RCTs in establishing efficacy. 393:210-211. 2019
The MANAGE trial – Authors' reply. 393:228-228. 2019
Canada's global health role – Authors' reply. 392:2350-2351. 2018
Discrepancies in guidelines for acute respiratory distress syndrome. 392:2550-2551. 2018
Oxygenation targets in acutely ill patients: still a matter of debate – Authors' reply. 392:2437-2438. 2018
GBD 2017 Causes of Death Collaborators. Global, regional, and national age-sex-specific mortality for 282 causes of death in;195 countries and territories, 1980-2017: a systematic analysis for the Global Burden of Disease Study 2017 (vol 392, pg 1736, 2018). 392:2170-2170. 2018
Association of dairy intake with cardiovascular disease and mortality in 21 countries from five continents (PURE): a prospective cohort study. 392:2288-2297. 2018
Department of Error. 392:2170-2170. 2018
Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial. 392:2269-2279. 2018
Global, regional, and national age-sex-specific mortality and life expectancy, 1950–2017: a systematic analysis for the Global Burden of Disease Study 2017. 392:1684-1735. 2018
Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the Global Burden of Disease Study 2017. 392:1736-1788. 2018
Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. 392:1923-1994. 2018
Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. 392:1859-1922. 2018
Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. 392:1789-1858. 2018
Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic analysis for the Global Burden of Disease Study 2017. 392:2091-2138. 2018
Patient outcomes after screw fixation of hip fractures – Authors' reply. 392:2265-2266. 2018
Population and fertility by age and sex for 195 countries and territories, 1950–2017: a systematic analysis for the Global Burden of Disease Study 2017. 392:1995-2051. 2018
Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. 392:1519-1529. 2018
Saudi visa trainees called home from Canada in diplomatic dispute. 392:815-816. 2018
Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis. 392:821-834. 2018
Esomeprazole and aspirin in Barrett's oesophagus (AspECT): a randomised factorial trial. 392:400-408. 2018
Urinary sodium excretion, blood pressure, cardiovascular disease, and mortality: a community-level prospective epidemiological cohort study. 392:496-506. 2018
Dabigatran in patients with myocardial injury after non-cardiac surgery (MANAGE): an international, randomised, placebo-controlled trial (vol 391, pg 2325, 2018). 392:30-30. 2018
Dabigatran in patients with myocardial injury after non-cardiac surgery (MANAGE): an international, randomised, placebo-controlled trial. 391:2325-2334. 2018
Efficacy and safety of guselkumab in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study. 391:2213-2224. 2018
Measuring performance on the Healthcare Access and Quality Index for 195 countries and territories and selected subnational locations: a systematic analysis from the Global Burden of Disease Study 2016. 391:2236-2271. 2018
Global governance of antimicrobial resistance. 391:1976-1978. 2018
Practice patterns and outcomes after stroke across countries at different economic levels (INTERSTROKE): an international observational study. 391:2019-2027. 2018
The gendered system of academic publishing. 391:1754-1756. 2018
Associations of fats and carbohydrates with cardiovascular disease and mortality—PURE and simple? – Authors' reply. 391:1681-1682. 2018
Canada's global health role: supporting equity and global citizenship as a middle power. 391:1736-1748. 2018
Mortality and morbidity in acutely ill adults treated with liberal versus conservative oxygen therapy (IOTA): a systematic review and meta-analysis. 391:1693-1705. 2018
Atraumatic versus conventional lumbar puncture needles: a systematic review and meta-analysis. 391:1197-1204. 2018
Cardiovascular, respiratory, and related disorders: key messages from Disease Control Priorities, 3rd edition. 391:1224-1236. 2018
Evidence-based guidelines for supportive care of patients with Ebola virus disease. 391:700-708. 2018
Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial (vol 391, pg 205, 2017). 391:204-204. 2018
Hyperparathyroidism. 391:168-178. 2018
Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial. 391:205-218. 2018
Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial. 391:219-229. 2018
Health workers and the weaponisation of health care in Syria: a preliminary inquiry for The Lancet –American University of Beirut Commission on Syria. 390:2516-2526. 2017
The effect of physical activity on mortality and cardiovascular disease in 130 000 people from 17 high-income, middle-income, and low-income countries: the PURE study. 390:2643-2654. 2017
On evidence-based medicine Reply. 390:2245-2246. 2017
Associations of fats and carbohydrate intake with cardiovascular disease and mortality in 18 countries from five continents (PURE): a prospective cohort study. 390:2050-2062. 2017
Continuous glucose monitoring in pregnant women with type 1 diabetes (CONCEPTT): a multicentre international randomised controlled trial. 390:2347-2359. 2017
Fruit, vegetable, and legume intake, and cardiovascular disease and deaths in 18 countries (PURE): a prospective cohort study. 390:2037-2049. 2017
Indigenous health data and the path to healing. 390:2022-2023. 2017
On evidence-based medicine – Authors' reply. 390:2245-2246. 2017
Department of Error. 390:e38-e38. 2017
Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. 390:1949-1961. 2017
Department of Error. 390:e23-e23. 2017
Global, regional, and national age-sex specific mortality for 264 causes of death, 1980–2016: a systematic analysis for the Global Burden of Disease Study 2016. 390:1151-1210. 2017
Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. 390:1345-1422. 2017
Global, regional, and national disability-adjusted life-years (DALYs) for 333 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. 390:1260-1344. 2017
Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. 390:1211-1259. 2017
Global, regional, and national under-5 mortality, adult mortality, age-specific mortality, and life expectancy, 1970–2016: a systematic analysis for the Global Burden of Disease Study 2016. 390:1084-1150. 2017
Measuring progress and projecting attainment on the basis of past trends of the health-related Sustainable Development Goals in 188 countries: an analysis from the Global Burden of Disease Study 2016. 390:1423-1459. 2017
Optimal timing of an invasive strategy in patients with non-ST-elevation acute coronary syndrome: a meta-analysis of randomised trials. 390:737-746. 2017
Procalcitonin-guided decision making for duration of antibiotic therapy in neonates with suspected early-onset sepsis: a multicentre, randomised controlled trial (NeoPIns). 390:871-881. 2017
Eliminating acute rheumatic fever and rheumatic heart disease. 390:212-213. 2017
Evidence for underuse of effective medical services around the world. 390:169-177. 2017
Healthcare Access and Quality Index based on mortality from causes amenable to personal health care in 195 countries and territories, 1990–2015: a novel analysis from the Global Burden of Disease Study 2015. 390:231-266. 2017
Levers for addressing medical underuse and overuse: achieving high-value health care. 390:191-202. 2017
Progress in evidence-based medicine: a quarter century on. 390:415-423. 2017
Achieved blood pressure and cardiovascular outcomes in high-risk patients: results from ONTARGET and TRANSCEND trials. 389:2226-2237. 2017
Fracture fixation in the operative management of hip fractures (FAITH): an international, multicentre, randomised controlled trial. 389:1519-1527. 2017
On the economics of managing blood pressure. 389:1294-1295. 2017
Palliative care in humanitarian crises: always something to offer. 389:1498-1499. 2017
Prolonged glucocorticoid treatment in acute respiratory distress syndrome. 389:1516-1516. 2017
Risk of mortality and stroke after atrial fibrillation – Authors' reply. 389:907-907. 2017
Occurrence of death and stroke in patients in 47 countries 1 year after presenting with atrial fibrillation: a cohort study (vol 388, pg 1161, 2016). 389:602-602. 2017
Understanding the impact of a new public health approach to end-of-life care: a qualitative study of a community led intervention. 389:S88-S88. 2017
3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial. 389:1399-1409. 2017
Nurturing care: promoting early childhood development. 389:91-102. 2017
Should recommendations about starting inhaled corticosteroid treatment for mild asthma be based on symptom frequency: a post-hoc efficacy analysis of the START study. 389:157-166. 2017
The INTERSTROKE study on risk factors for stroke – Authors' reply. 389:36-36. 2017
Interpretation of the evidence for the efficacy and safety of statin therapy. 388:2532-2561. 2016
Benralizumab, an anti-interleukin-5 receptor a monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. 388:2128-2141. 2016
Global, regional, national, and selected subnational levels of stillbirths, neonatal, infant, and under-5 mortality, 1980-2015: a systematic analysis for the Global Burden of Disease Study 2015.. 388:1725-1774. 2016
Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. 388:2128-2141. 2016
Edoxaban versus enoxaparin–warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): a randomised, open-label, phase 3b trial. 388:1995-2003. 2016
Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. 388:1659-1724. 2016
Global, regional, and national disability-adjusted life-years (DALYs) for 315 diseases and injuries and healthy life expectancy (HALE), 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. 388:1603-1658. 2016
Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. 388:1545-1602. 2016
Global, regional, and national levels of maternal mortality, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. 388:1775-1812. 2016
Global, regional, national, and selected subnational levels of stillbirths, neonatal, infant, and under-5 mortality, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015. 388:1725-1774. 2016
Hypertrophic scarring: the greatest unmet challenge after burn injury. 388:1427-1436. 2016
Measuring the health-related Sustainable Development Goals in 188 countries: a baseline analysis from the Global Burden of Disease Study 2015. 388:1813-1850. 2016
Sodium and cardiovascular disease – Authors' reply. 388:2113-2114. 2016
Occurrence of death and stroke in patients in 47 countries 1 year after presenting with atrial fibrillation: a cohort study. 388:1161-1169. 2016
Why do people not take life-saving medications? The case of statins. 388:943-945. 2016
Global and regional effects of potentially modifiable risk factors associated with acute stroke in 32 countries (INTERSTROKE): a case-control study. 388:761-775. 2016
Unresolved issues in Canada's law on physician-assisted dying. 388:545-547. 2016
Associations of urinary sodium excretion with cardiovascular events in individuals with and without hypertension: a pooled analysis of data from four studies. 388:465-475. 2016
UN High-Level Meeting on antimicrobials—what do we need?. 388:218-220. 2016
The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation study. 387:2302-2311. 2016
Breastfeeding in the 21st century. 387:2088-2089. 2016
Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial. 387:1066-1074. 2016
Availability and affordability of cardiovascular disease medicines and their effect on use in high-income, middle-income, and low-income countries: an analysis of the PURE study data.. 387:61-69. 2016
Availability and affordability of cardiovascular disease medicines and their effect on use in high-income, middle-income, and low-income countries: an analysis of the PURE study data. 387:61-69. 2016
International cooperation to improve access to and sustain effectiveness of antimicrobials. 387:296-307. 2016
Late preterm rupture of membranes: it pays to wait. 387:406-408. 2016
Outcomes after thrombus aspiration for ST elevation myocardial infarction: 1-year follow-up of the prospective randomised TOTAL trial. 387:127-135. 2016
Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. 386:2287-2323. 2015
Alcohol consumption and cardiovascular disease, cancer, injury, admission to hospital, and mortality: a prospective cohort study. 386:1945-1954. 2015
Global, regional, and national disability-adjusted life years (DALYs) for 306 diseases and injuries and healthy life expectancy (HALE) for 188 countries, 1990–2013: quantifying the epidemiological transition. 386:2145-2191. 2015
Radiation exposure in relation to the arterial access site used for diagnostic coronary angiography and percutaneous coronary intervention: a systematic review and meta-analysis. 386:2192-2203. 2015
Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. 386:1341-1352. 2015
Controversies in faith and health care. 386:1776-1785. 2015
Understanding the roles of faith-based health-care providers in Africa: review of the evidence with a focus on magnitude, reach, cost, and satisfaction. 386:1765-1775. 2015
Is crowdfunding a viable source of clinical trial research funding? (vol 386, pg 338, 2015). 386:1136-1136. 2015
Corticosteroid therapy for pneumonia – Author's reply. 386:956-956. 2015
Department of Error. 386:1136-1136. 2015
Methylprednisolone in patients undergoing cardiopulmonary bypass (SIRS): a randomised, double-blind, placebo-controlled trial. 386:1243-1253. 2015
Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials. 386:541-551. 2015
Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. 386:743-800. 2015
Is crowdfunding a viable source of clinical trial research funding?. 386:338-338. 2015
Prognostic value of grip strength: findings from the Prospective Urban Rural Epidemiology (PURE) study. 386:266-273. 2015
The World Heart Federation's vision for worldwide cardiovascular disease prevention. 386:399-402. 2015
Coronary intervention: radial artery access comes of age. 385:2437-2439. 2015
Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial. 385:2067-2076. 2015
Living kidney donation: outcomes, ethics, and uncertainty. 385:2003-2013. 2015
Worldwide access to treatment for end-stage kidney disease: a systematic review. 385:1975-1982. 2015
Adjunct prednisone therapy for patients with community-acquired pneumonia: a multicentre, double-blind, randomised, placebo-controlled trial. 385:1511-1518. 2015
Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174 000 participants in 27 randomised trials. 385:1397-1405. 2015
Musculoskeletal trauma and all-cause mortality in India: a multicentre prospective cohort study. 385:S30-S30. 2015
Population control policies in Iran - Author's reply.. 385:1072. 2015
Disseminated blastomycosis with cutaneous involvement in a Canadian railroad worker. 385:883-883. 2015
Effects of blood pressure lowering on cardiovascular risk according to baseline body-mass index: a meta-analysis of randomised trials. 385:867-874. 2015
Effects of intensive glycaemic control on ischaemic heart disease – Authors' reply. 385:1180-1181. 2015
Cardioverter defibrillator implantation without induction of ventricular fibrillation: a single-blind, non-inferiority, randomised controlled trial (SIMPLE). 385:785-791. 2015
The burden of disease in older people and implications for health policy and practice. 385:549-562. 2015
Trading health for oil? Uganda should not export its health workers. 385:e13-e13. 2015
Global, regional, and national age–sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. 385:117-171. 2015
Iran: the health cost of a political order.. 384:1926-1927. 2014
Antepartum dalteparin versus no antepartum dalteparin for the prevention of pregnancy complications in pregnant women with thrombophilia (TIPPS): a multinational open-label randomised trial. 384:1673-1683. 2014
Effects of intensive glycaemic control on ischaemic heart disease: analysis of data from the randomised, controlled ACCORD trial. 384:1936-1941. 2014
Ebola control: effect of asymptomatic infection and acquired immunity. 384:1499-1500. 2014
The safety of addition of nitrous oxide to general anaesthesia in at-risk patients having major non-cardiac surgery (ENIGMA-II): a randomised, single-blind trial. 384:1446-1454. 2014
Global, regional, and national incidence and mortality for HIV, tuberculosis, and malaria during 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. 384:1005-1070. 2014
Global, regional, and national levels and causes of maternal mortality during 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. 384:980-1004. 2014
Global, regional, and national levels of neonatal, infant, and under-5 mortality during 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. 384:957-979. 2014
Blood pressure-lowering treatment based on cardiovascular risk: a meta-analysis of individual patient data. 384:591-598. 2014
International comparisons of acute myocardial infarction. 384:304-304. 2014
Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials. 383:2127-2135. 2014
Radiotherapy for breast cancer, the TARGIT-A trial. 383:1716-1717. 2014
Burns in children: standard and new treatments. 383:1168-1178. 2014
Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. 383:955-962. 2014
Compression stockings to prevent post-thrombotic syndrome: a randomised placebo-controlled trial. 383:880-888. 2014
Premature mortality in patients with epilepsy. 383:511-511. 2014
Global and regional burden of stroke during 1990–2010: findings from the Global Burden of Disease Study 2010. 383:245-255. 2014
Cangrelor: a new CHAMPION for percutaneous coronary intervention. 382:1960-1962. 2013
Experiencing regrets in clinical practice. 382:1553-1554. 2013
Global health governance after 2015. 382:1018-1018. 2013
Prevalence of abuse and intimate partner violence surgical evaluation (PRAISE) in orthopaedic fracture clinics: a multinational prevalence study. 382:866-876. 2013
Blood-pressure targets in patients with recent lacunar stroke: the SPS3 randomised trial. 382:507-515. 2013
Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. 382:780-789. 2013
Extra-couple HIV transmission in sub-Saharan Africa: a mathematical modelling study of survey data. 381:1561-1569. 2013
Effects of folic acid supplementation on overall and site-specific cancer incidence during the randomised trials: meta-analyses of data on 50 000 individuals. 381:1029-1036. 2013
Ongoing bleeding in acute intracerebral haemorrhage. 381:152-152. 2013
Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. 380:2197-2223. 2012
Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. 380:2095-2128. 2012
Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. 380:2163-2196. 2012
Pulse oximetry screening for critical congenital heart defects. 380:1305-1306. 2012
Advances and future directions for management of trauma patients with musculoskeletal injuries. 380:1109-1119. 2012
Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. 380:572-580. 2012
The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. 380:581-590. 2012
WHO's undermining tobacco control. 380:727-728. 2012
Is regression to normoglycaemia clinically important?. 379:2216-2218. 2012
The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial. 379:2352-2363. 2012
Does aspirin really reduce the risk of colon cancer?. 379:1586-1587. 2012
Surfactant treatment for spontaneously breathing preterm infants. 379:1589-1589. 2012
A flawed Bill with a hidden purpose. 379:999-999. 2012
AIDA STEMI: no benefit for intracoronary abciximab. 379:875-877. 2012
Burn size and survival probability in paediatric patients in modern burn care: a prospective observational cohort study. 379:1013-1021. 2012
Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trials. 379:432-444. 2012
How the Health and Social Care Bill 2011 would end entitlement to comprehensive health care in England. 379:387-389. 2012
Erratum: Plasma HDL cholesterol and risk of myocardial infarction: A mendelian randomisation study (The Lancet (2012) DOI:10.1016/S0140-6736(12) 60312-2). 380:564. 2012
Idrabiotaparinux treatment for venous thromboembolism. 379:96-98. 2012
A framework convention on obesity control?. 378:2068-2068. 2011
No evidence that patient choice in the NHS saves lives. 378:2057-2060. 2011
Ending medical complicity in state-sponsored torture. 378:1535-1537. 2011
Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey. 378:1231-1243. 2011
Aerosol drug delivery: developments in device design and clinical use – Authors' reply. 378:982-982. 2011
Continued neglect of ageing of HIV epidemic at UN meeting. 378:768-768. 2011
Radial versus femoral access in acute coronary syndromes – Authors' reply. 378:661-662. 2011
Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. 378:771-784. 2011
Radial versus femoral access for coronary angiography and intervention in patients with acute coronary syndromes (RIVAL): a randomised, parallel group, multicentre trial. (vol 377, pg 1409, 2011). 378:30-30. 2011
Body-mass index, abdominal adiposity, and cardiovascular risk. 378:226-227. 2011
Department of Error. 378:30-30. 2011
Aspirin in the prevention of cancer. 377:1649-1650. 2011
Ageing faster with AIDS in Africa. 377:1131-1133. 2011
Department of Error. 377:1408-1408. 2011
Radial versus femoral access for coronary angiography and intervention in patients with acute coronary syndromes (RIVAL): a randomised, parallel group, multicentre trial. 377:1409-1420. 2011
Aerosol drug delivery: developments in device design and clinical use. 377:1032-1045. 2011
New drug development. 377:901-902. 2011
The importance of early treatment with tranexamic acid in bleeding trauma patients: an exploratory analysis of the CRASH-2 randomised controlled trial. 377:1096-1101.e2. 2011
Stemming the global tsunami of cardiovascular disease. 377:529-532. 2011
Double-dose clopidogrel in patients undergoing PCI for ACS – Authors' reply. 377:298-298. 2011
Effects of a mobile phone short message service on antiretroviral treatment adherence in Kenya (WelTel Kenya1): a randomised trial. 376:1838-1845. 2010
Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials. 376:1670-1681. 2010
How generalisable is INTERSTROKE? – Authors' reply. 376:1539-1539. 2010
Antiphospholipid syndrome. 376:1498-1509. 2010
Can we increase male involvement in AIDS treatment?. 376:1302-1302. 2010
Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial. 376:1233-1243. 2010
Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. 376:975-983. 2010
Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. 376:419-430. 2010
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial. 376:23-32. 2010
Low-dose combination therapy with rosiglitazone and metformin to prevent type 2 diabetes mellitus (CANOE trial): a double-blind randomised controlled study. 376:103-111. 2010
Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study. 376:112-123. 2010
More insights on the dysglycaemia–cardiovascular connection. 375:2195-2196. 2010
Mendelian randomisation, triglycerides, and CHD. 375:1584-1586. 2010
Is there an ethical obligation to complete polio eradication?. 375:1340-1341. 2010
Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. 375:807-815. 2010
InFACT: a global critical care research response to H1N1. 375:11-13. 2010
Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trial. 374:2055-2063. 2009
Directly observed antiretroviral therapy: a systematic review and meta-analysis of randomised clinical trials. 374:2064-2071. 2009
Anticoagulants for patients with prosthetic heart valves – Authors' reply. 374:1499-1500. 2009
Methodologists are not qualified to write clinical guidelines – Authors' reply. 374:1327-1327. 2009
Challenges in evaluating surgical innovation. 374:1097-1104. 2009
Evaluation and stages of surgical innovations. 374:1089-1096. 2009
No surgical innovation without evaluation: the IDEAL recommendations. 374:1105-1112. 2009
Otamixaban in acute coronary syndromes. 374:762-764. 2009
The Indian Polycap Study (TIPS) – Authors' reply. 374:782-782. 2009
To cement or not in hip fracture surgery?. 374:1047-1049. 2009
Albuminuria in chronic heart failure: prevalence and prognostic importance. 374:543-550. 2009
Antithrombotic management of patients with prosthetic heart valves: current evidence and future trends. 374:565-576. 2009
From BODE to ADO to outcomes in multimorbid COPD patients. 374:667-668. 2009
Phosphodiesterase-4 inhibition in COPD. 374:665-667. 2009
Rivaroxaban versus enoxaparin after total knee arthroplasty. 374:681-681. 2009
Rivaroxaban versus enoxaparin after total knee arthroplasty – Authors' reply. 374:683-683. 2009
Lipid lowering for primary prevention (vol 373, pg 1152, 2009). 374:28-28. 2009
Clinical experts or methodologists to write clinical guidelines?. 374:273-275. 2009
Expanding HIV care in Africa: making men matter. 374:275-276. 2009
Does ratification of human-rights treaties have effects on population health?. 373:1987-1992. 2009
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. 373:1673-1680. 2009
Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial. 373:1341-1351. 2009
Interference, intimidation, and measuring mortality in war. 373:1320-1322. 2009
Lipid lowering for primary prevention. 373:1152-1155. 2009
Make the money work for health in sub-Saharan Africa. 373:1174-1174. 2009
Responding to child maltreatment – Authors' reply. 373:1251-1251. 2009
Antenatal corticosteroids to prevent preterm birth – Authors' reply. 373:894-894. 2009
Lancet Steering Group on the occupied Palestinian territory. 373:788-790. 2009
A vision statement on guideline development for respiratory disease: the example of COPD. 373:774-779. 2009
Telmisartan in high-risk patients intolerant of ACE inhibitors – Authors' reply. 373:459-459. 2009
Adjuvant external beam radiotherapy in the treatment of endometrial cancer (MRC ASTEC and NCIC CTG EN.5 randomised trials): pooled trial results, systematic review, and meta-analysis. 373:137-146. 2009
Interventions to prevent child maltreatment and associated impairment. 373:250-266. 2009
Recognising and responding to child maltreatment. 373:167-180. 2009
Multiple courses of antenatal corticosteroids for preterm birth (MACS): a randomised controlled trial. 372:2143-2151. 2008
Renal outcomes in the ONTARGET study – Authors' reply. 372:2020-2021. 2008
Sustainability science: an integrated approach for health-programme planning. 372:1579-1589. 2008
Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial (vol 372, pg 1174, 2008). 372:1384-1384. 2008
Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. 372:1174-1183. 2008
Exhaled nitric oxide in guideline-based asthma management. 372:1015-1017. 2008
Supporting the delivery of cost-effective interventions in primary health-care systems in low-income and middle-income countries: an overview of systematic reviews. 372:928-939. 2008
The coming of age of asthma guidelines. 372:1021-1022. 2008
β-blocker therapy in non-cardiac surgery – Authors' reply. 372:1146-1146. 2008
Guidelines for anticoagulant use in acute coronary syndromes – Authors' reply. 372:533-534. 2008
Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. 372:547-553. 2008
Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study): a case-control study. 372:224-233. 2008
Selective factor Xa inhibition for thromboprophylaxis. 372:6-8. 2008
Effects of extended-release metoprolol succinate in patients undergoing non-cardiac surgery (POISE trial): a randomised controlled trial. 371:1839-1847. 2008
Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). 371:1675-1684. 2008
Guidelines for anticoagulant use in acute coronary syndromes. 371:1559-1561. 2008
Cardiotoxicity associated with sunitinib. 371:1244-1244. 2008
Treatment and outcomes of acute coronary syndromes in India (CREATE): a prospective analysis of registry data. 371:1435-1442. 2008
Endoscopic treatments for gastro-oesophageal reflux disease. 371:965-966. 2008
Effects of policy options for human resources for health: an analysis of systematic reviews. 371:668-674. 2008
Should active recruitment of health workers from sub-Saharan Africa be viewed as a crime?. 371:685-688. 2008
An overview of mortality and sequelae of preterm birth from infancy to adulthood. 371:261-269. 2008
Efficacy of cholesterol-lowering therapy in 18 686 people with diabetes in 14 randomised trials of statins: a meta-analysis. 371:117-125. 2008
A wake-up call for global access to salvage HIV drug regimens. 370:1885-1887. 2007
Do human rights matter to health? (vol 370, pg 521, 2007). 370:1686-1686. 2007
Patient-important outcomes in diabetes—time for consensus. 370:1104-1106. 2007
Sequential regimens for Helicobacter pylori eradication. 370:1010-1012. 2007
Use of evidence in WHO recommendations. 370:825-826. 2007
Use of evidence in WHO recommendations – Authors' reply. 370:826-827. 2007
Do human rights matter to health?. 370:521-527. 2007
History, principles, and practice of health and human rights. 370:449-455. 2007
Neglected diseases, civil conflicts, and the right to health. 370:619-627. 2007
Not a broken heart. 370:628-628. 2007
Use of evidence in WHO recommendations.. 369:1883-1889. 2007
Use of evidence in WHO recommendations. 369:1883-1889. 2007
Thromboembolism prevention in ischaemic stroke. 369:1413-1415. 2007
Prevention of vascular events in atrial fibrillation – Authors' reply. 369:106-106. 2007
Strategies to avoid the loss of developmental potential in more than 200 million children in the developing world. 369:229-242. 2007
The DREAM trial – Authors' reply. 368:2050-2051. 2006
Asthma as a disease concept. 368:1415-1416. 2006
Thioguanine versus mercaptopurine in childhood ALL. 368:1304-1306. 2006
Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. 368:1096-1105. 2006
Helicobacter pylori and gastro-oesophageal reflux disease – Authors' reply. 368:986-987. 2006
Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials. 368:581-588. 2006
ESPRIT trial. 368:447-447. 2006
Pharmacological management of mild or moderate persistent asthma. 368:794-803. 2006
Tobacco use and risk of myocardial infarction in 52 countries in the INTERHEART study: a case-control study. 368:647-658. 2006
Effect of patient's sex on risk of recurrent venous thromboembolism: a meta-analysis. 368:371-378. 2006
The decline of academic medicine. 368:284-284. 2006
Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. 367:1903-1912. 2006
Gastro-oesophageal reflux disease. 367:2086-2100. 2006
Deeper lessons from the CMAJ debacle. 367:1551-1553. 2006
Free doctors and medical students detained in Nepal. 367:1730-1730. 2006
Obesity and risk of myocardial infarction: the INTERHEART study – Author's reply. 367:1054-1054. 2006
Syndromic approach for treatment of STIs: time for a change. 367:1380-1381. 2006
Aspirin resistance. 367:606-617. 2006
Adherence to candesartan and placebo and outcomes in chronic heart failure in the CHARM programme: double-blind, randomised, controlled clinical trial. 366:2005-2011. 2005
Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. 366:2087-2106. 2005
Obesity and the risk of myocardial infarction in 27 000 participants from 52 countries: a case-control study. 366:1640-1649. 2005
Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins. 366:1267-1278. 2005
Haemoglobin E β thalassaemia in Sri Lanka. 366:1467-1470. 2005
Adjuvant trastuzumab for HER2-positive breast cancer. 366:634-634. 2005
Combination antibiotic susceptibility testing to treat exacerbations of cystic fibrosis associated with multiresistant bacteria: a randomised, double-blind, controlled clinical trial. 366:463-471. 2005
Deep vein thrombosis. 366:118-118. 2005
Blinded by pressure and pain. 365:2244-2244. 2005
Long-term survival and vascular event risk after transient ischaemic attack or minor ischaemic stroke: a cohort study. 365:2098-2104. 2005
Effectiveness of home visitation by public-health nurses in prevention of the recurrence of child physical abuse and neglect: a randomised controlled trial. 365:1786-1793. 2005
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. 365:1687-1717. 2005
Selective head cooling after neonatal encephalopathy. 365:1619-1619. 2005
Homocysteine and stroke. 365:194-196. 2005
INTERHEART. 365:117-117. 2005
INTERHEART. 365:118-118. 2005
INTERHEART. 365:119-120. 2005
Zero tolerance for domestic violence. 365:120-120. 2005
Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study (vol 364, pg 937m 2004). 364:2020-2020. 2004
Department of Error. 364:2020-2020. 2004
Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study (vol 364, pg 937, 2004). 364:1938-1938. 2004
Implications of the draft European Union services directive for health care. 364:1200-1202. 2004
Use of research to inform public policymaking. 364:1615-1621. 2004
Association of psychosocial risk factors with risk of acute myocardial infarction in 11 119 cases and 13 648 controls from 52 countries (the INTERHEART study): case-control study. 364:953-962. 2004
B-Aware:recall of intra-operative events. 364:840-840. 2004
B-Aware:recall of intra-operative events. 364:841-841. 2004
Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. 364:937-952. 2004
Informed choices for attaining the Millennium Development Goals: towards an international cooperative agenda for health-systems research. 364:997-1003. 2004
Infant wellbeing at 2 years of age in the Growth Restriction Intervention Trial (GRIT): multicentred randomised controlled trial. 364:513-520. 2004
The McMaster- Lancet health and peace conferences. 364:311-312. 2004
Selective quotation of evidence in vaccines research. 363:1738-1738. 2004
Improving patients' safety locally: changing clinician behaviour. 363:1224-1230. 2004
Ximelagatran or warfarin in atrial fibrillation?. 363:734-734. 2004
Innovation and placebos in research: a new design of clinical trial. 362:2036-2037. 2003
Fondaparinux and prevention of venous thromboembolism after orthopaedic surgery.. 362:1581. 2003
Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. 362:1527-1535. 2003
Fondaparinux and prevention of venous thromboembolism after orthopaedic surgery. 362:1582-1583. 2003
The CHARM programme. 362:1675-1676. 2003
The CHARM programme. 362:1678-1679. 2003
Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. 362:777-781. 2003
Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. 362:772-776. 2003
Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. 362:767-771. 2003
Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. 362:759-766. 2003
The public health implications of world trade negotiations on the general agreement on trade in services and public services. 362:1072-1075. 2003
Assessment of efficacy of varicocele repair for male subfertility: a systematic review. 361:1849-1852. 2003
Effect of enalapril on 12-year survival and life expectancy in patients with left ventricular systolic dysfunction: a follow-up study. 361:1843-1848. 2003
Early intervention with budesonide in mild persistent asthma: a randomised, double-blind trial. 361:1071-1076. 2003
Prognostic importance of weight loss in chronic heart failure and the effect of treatment with angiotensin-converting-enzyme inhibitors: an observational study. 361:1077-1083. 2003
Heart Protection Study. 361:528-528. 2003
Heart Protection Study. 361:530-530. 2003
Mortality and indicators of traffic-related air pollution. 361:430-430. 2003
Breastfeeding, atopy, and asthma.. 361:174. 2003
Erratum: Effects of long-term treatment with angiotensin-converting-enzyme inhibitors in the presence or absence of aspirin: A systematic review (Lancet (October 5) (1037)). 361:90. 2003
Breastfeeding, atopy, and asthma. 361:175-176. 2003
Tobacco money: up in smoke?. 360:1981-1981. 2002
Association between children's experience of socioeconomic disadvantage and adult health: a life-course study. 360:1640-1645. 2002
Do editors live up to the Sept 10, 2001, expectations?. 360:1606-1606. 2002
Do editors live up to the Sept 10, 2001, expectations?. 360:1605-1606. 2002
Fondaparinux versus enoxaparin for prevention of venous thromboembolism. 360:1603-1604. 2002
Fondaparinux versus enoxaparin for prevention of venous thromboembolism. 360:1605-1605. 2002
Erratum: Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism after elective hip-replacement surgery: A rondomised double-blind trial (Lancet (May 18) (1721)). 360:1102. 2002
Effects of long-term treatment with angiotensin-converting-enzyme inhibitors in the presence or absence of aspirin: a systematic review. 360:1037-1043. 2002
Long-term relation between breastfeeding and development of atopy and asthma in children and young adults: a longitudinal study. 360:901-907. 2002
Prenatal exclusion of β thalassaemia major by examination of maternal plasma. 360:998-1000. 2002
Who is fooling us?. 360:873-874. 2002
Direct thrombin inhibitors in acute coronary syndromes. 360:491-492. 2002
Direct thrombin inhibitors in acute coronary syndromes. 360:492-492. 2002
How to spread information. 360:493-493. 2002
Ibuprofen prophylaxis in preterm neonates. 360:492-492. 2002
Effect of T-cell peptides derived from Fel d 1 on allergic reactions and cytokine production in patients sensitive to cats: a randomised controlled trial. 360:47-53. 2002
Two decades of progress in preventing vascular disease. 360:2-3. 2002
What kind of evidence do we need to justify humanitarian medical aid?. 360:330-333. 2002
Blood pressure and cardiovascular risk in the HOPE study. 359:2118-2118. 2002
Blood pressure and cardiovascular risk in the HOPE study. 359:2117-2118. 2002
Helicobacter pylori and peptic-ulcer disease. 359:1943-1943. 2002
Helicobacter pylori and peptic-ulcer disease. 359:1944-1944. 2002
The tip of the iceberg?. 359:2194-2194. 2002
Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism after elective hip-replacement surgery: a randomised double-blind trial. 359:1721-1726. 2002
Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery: a randomised double-blind comparison. 359:1715-1720. 2002
Market forces in public health. 359:1363-1364. 2002
Clopidogrel and percutaneous coronary intervention. 359:169-169. 2002
Clopidogrel and percutaneous coronary intervention. 359:169-169. 2002
Direct thrombin inhibitors in acute coronary syndromes: principal results of a meta-analysis based on individual patients' data. 359:294-302. 2002
Effect of visual-spatial ability on learning of spatially-complex surgical skills. 359:230-231. 2002
Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis. 359:14-22. 2002
Blood-pressure reduction and cardiovascular risk in HOPE study. 358:2130-2131. 2001
Cardiopulmonary resuscitation directives on admission to intensive-care unit: an international observational study. 358:1941-1945. 2001
Not a drop to drink in the Aral Sea. 358:1649-1649. 2001
Risk factors, atherosclerosis, and cardiovascular disease among Aboriginal people in Canada: the Study of Health Assessment and Risk Evaluation in Aboriginal Peoples (SHARE-AP). 358:1147-1153. 2001
Effect of world trade on public health. 358:1097-1097. 2001
Tinzaparin in acute ischaemic stroke (TAIST): a randomised aspirin-controlled trial. 358:702-710. 2001
Broad-spectrum antibiotics in ORACLE. 358:502-502. 2001
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. 358:527-533. 2001
Extended-duration prophylaxis against venous thromboembolism after total hip or knee replacement: a meta-analysis of the randomised trials. 358:9-15. 2001
Behavioural problems in children who weigh 1000 g or less at birth in four countries. 357:1641-1643. 2001
Health and peace: time for a new discipline. 357:1460-1461. 2001
Venous thromboembolism after long flights: are airlines to blame?. 357:1461-1462. 2001
How medical students learn spatial anatomy. 357:363-364. 2001
Vitamin K in anticoagulation therapy. 357:637-637. 2001
Vitamin K in anticoagulation therapy. 357:638-638. 2001
Term breech trial.. 357:225. 2001
Term breech trial. 357:227-228. 2001
Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. 356:1955-1964. 2000
Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsìveness, and the late asthmatic response. 356:2144-2148. 2000
Effects of recombinant human interleukin-12 on eosinophils, airway hyper-responsiveness, and the late asthmatic response. 356:2149-2153. 2000
Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial. 356:2037-2044. 2000
Rewriting the regulations: how the World Trade Organisation could accelerate privatisation in health-care systems. 356:1995-2000. 2000
Intracranial haemorrhage with bolus thrombolytic agents. 356:1848-1848. 2000
Intracranial haemorrhage with bolus thrombolytic agents. 356:1850-1850. 2000
Treatment of warfarin-associated coagulopathy with oral vitamin K: a randomised controlled trial. 356:1551-1553. 2000
Planned caesarean section versus planned vaginal birth for breech presentation at term: a randomised multicentre trial. 356:1375-1383. 2000
Management of unstable angina and myocardial infarction. 356:1193-1194. 2000
Recognition of premenstrual dysphoric disorder and its treatment. 356:1126-1127. 2000
Erratum: Unfractionated heparin and low-molecular-weight heparin in acute coronary syndrome without ST elevation: A meta-analysis (Lancet (2000) 3 June (1936)). 356:600. 2000
Unfractionated heparin and low-molecular-weight heparin in acute coronary syndrome without ST elevation: a meta-analysis (vol 355, pg 1936, 2000). 356:600-600. 2000
Long-term safety and efficacy of omeprazole in gastro-oesophageal reflux disease. 356:610-612. 2000
Risk of intracranial haemorrhage with bolus versus infusion thrombolytic therapy: a meta-analysis. 356:449-454. 2000
Treatment of severe systemic lupus erythematosus with high-dose chemotherapy and haemopoietic stem-cell transplantation: a phase I study. 356:701-707. 2000
A commitment to curbing the pandemic of cardiovascular disease. 356:347-347. 2000
Differences in risk factors, atherosclerosis, and cardiovascular disease between ethnic groups in Canada: the Study of Health Assessment and Risk in Ethnic groups (SHARE). 356:279-284. 2000
Medical migration: who are the real losers?. 356:245-246. 2000
Stability and sterility of recombinant tissue plasminogen activator at −30°C. 355:2221-2221. 2000
Unfractionated heparin and low-molecular-weight heparin in acute coronary syndrome without ST elevation: a meta-analysis. 355:1936-1942. 2000
Effect of population screening and treatment for Helicobacter pylori on dyspepsia and quality of life in the community: a randomised controlled trial. 355:1665-1669. 2000
Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. 355:1575-1581. 2000
Short-acting inhaled β-agonists: to be taken regularly or as needed?. 355:1658-1659. 2000
Worrisome striae. 355:1692-1692. 2000
Fetal growth restriction. 355:1366-1367. 2000
Nosocomial influenza infection. 355:1187-1188. 2000
Pertussis transmission in England and Wales. 355:1553-1553. 2000
Pertussis transmission in England and Wales. 355:1553-1554. 2000
The HOPE study and diabetes. 355:1181-1181. 2000
The HOPE study and diabetes. 355:1183-1184. 2000
Stress hyperglycaemia and increased risk of death after myocardial infarction in patients with and without diabetes: a systematic overview. 355:773-778. 2000
Management of unstable coronary-artery disease. 355:572-572. 2000
Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. 355:253-259. 2000
Impact of immunisation on pertussis transmission in England and Wales. 355:285-286. 2000
Risk of congenital malformations associated with treatment of asthma during early pregnancy. 355:119-119. 2000
Albert Einstein's brain.. 354:1821-1822. 1999
Albert Einstein's brain. 354:1822-1822. 1999
How the World Trade Organisation is shaping domestic policies in health care. 354:1889-1892. 1999
Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. 354:1896-1900. 1999
Symptoms of reproductive-tract infection—not all that they seem to be. 354:1745-1746. 1999
18F-fluorodeoxyglucose positron tomography in diagnosis of paediatric inflammatory bowel disease. 354:836-837. 1999
Lifeline - Salim Yusuf. 354:876-876. 1999
18F-fluorodeoxyglucose positron tomography in diagnosis of paediatric inflammatory bowel disease. 354:836-837. 1999
Diagnosis of left-ventricular dysfunction from induced sputum examination. 354:833-834. 1999
Erratum: The exceptional brain of Albert Einstein (The Lancet (1999) June 19 (2149)). 354:258. 1999
Homocysteine and vascular disease. 354:407-413. 1999
Low-dose and high-dose acetylsalicylic acid for patients undergoing carotid endarterectomy: a randomised controlled trial. 353:2179-2184. 1999
The exceptional brain of Albert Einstein. 353:2149-2153. 1999
Erratum: New antithrombotic agents (The Lancet (1999) April 24 (1431)). 353:1804. 1999
New antithrombotic agents (vol 353, pg 1431, 1999). 353:1804-1804. 1999
Asthma exacerbations. 353:1443-1443. 1999
New antithrombotic agents. 353:1431-1436. 1999
Prognosis in acute pulmonary embolism. 353:1375-1376. 1999
Effects of recombinant hirudin (lepirudin) compared with heparin on death, myocardial infarction, refractory angina, and revascularisation procedures in patients with acute myocardial ischaemia without ST elevation: a randomised trial. 353:429-438. 1999
Preventive medicine in a diabetes clinic: an opportunity to make a difference. 353:606-608. 1999
Leukotrienes and the brain. 352:1487-1488. 1998
Variations between countries in invasive cardiac procedures. 352:1469-1469. 1998
Variations between countries in invasive cardiac procedures. 352:1470-1471. 1998
Polychemotherapy for early breast cancer: an overview of the randomised trials. 352:930-942. 1998
Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?. 352:609-613. 1998
Variations between countries in invasive cardiac procedures and outcomes in patients with suspected unstable angina or myocardial infarction without initial ST elevation. 352:507-514. 1998
Reappraisal of Malthus. 352:241-242. 1998
Meta-analysis. 351:1960-1960. 1998
Tamoxifen for early breast cancer: an overview of the randomised trials. 351:1451-1467. 1998
Male erectile dysfunction. 351:757-758. 1998
Overcoming the limitations of current meta-analysis of randomised controlled trials. 351:47-52. 1998
Randomised trial to assess safety and fetal outcome of early and midtrimester amniocentesis. 351:242-247. 1998
Adjuvant chemotherapy for localised resectable soft-tissue sarcoma of adults: meta-analysis of individual data. 350:1647-1654. 1997
Angiotensin-converting-enzyme inhibitors in early pregnancy. 350:1446-1447. 1997
Effect of prophylactic amiodarone on mortality after acute myocardial infarction and in congestive heart failure: meta-analysis of individual data from 6500 patients in randomised trials. 350:1417-1424. 1997
Descriptive epidemiology of asthma. 350:S1-S4. 1997
Epidemiology of childhood asthma. 350:1015-1020. 1997
Living a little more dangerously. 350:1164-1165. 1997
To treat or not to treat?. 350:820-821. 1997
Treatment of thalassaemia major with phenylbutyrate and hydroxyurea. 350:491-492. 1997
Intracoronary-stent placement for coronary artery disease.. 350:113-114. 1997
Amiodarone after myocardial infarction: EMIAT and CAMIAT trials.. 349:1767. 1997
Blood pressure in pregnancy and fetal growth.. 349:802. 1997
Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations: CAMIAT. 349:675-682. 1997
Treatment of mild asthma. 349:818-818. 1997
CAPRIE trial. 349:356-356. 1997
CAPRIE trial.. 349:354-355. 1997
Ambulatory blood pressure in pregnancy and fetal growth. 349:7-10. 1997
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). 348:1329-1339. 1996
Ovarian ablation in early breast cancer: overview of the randomised trials. 348:1189-1196. 1996
Risk factors for coronary heart disease in Asian Indians. 348:1242-1242. 1996
Increased fetal loss in women with heritable thrombophilia. 348:913-916. 1996
Meta-analysis of respiratory rehabilitation in chronic obstructive pulmonary disease. 348:1115-1119. 1996
Post-discharge deep-vein thrombosis after orthopaedic surgery. 348:1180-1180. 1996
Risk factors for acute myocardial infarction in Indians: a case-control study. 348:358-363. 1996
Systematic review of randomised trials of interventions to assist patients to follow prescriptions for medications. 348:383-386. 1996
Medicine and the media. 348:62-62. 1996
Dysglycaemia and risk of cardiovascular disease - Reply. 347:1834-1835. 1996
Dysglycaemia and risk of cardiovascular disease. 347:1833-1835. 1996
Dysglycaemia and risk of cardiovascular disease. 347:949-950. 1996
Hirudin and thrombosis prophylaxis. 347:632-633. 1996
Red-cell antibodies in pregnancy: evidence overturned. 347:485-486. 1996
Psychometric scores and persistence of irritable bowel after infectious diarrhoea. 347:150-153. 1996
Evidence-based medicine. 346:1300-1300. 1995
Evidence-based medicine. 346:1171-1172. 1995
Evidence-based medicine.. 346:839. 1995
Preventive health care. 345:1611-1615. 1995
Accuracy of clinical assessment of deep-vein thrombosis. 345:1326-1330. 1995
Report card from McMaster: student evaluation at a problem-based medical school. 345:899-902. 1995
Asthma deaths in New Zealand. 345:655-656. 1995
ISIS-4: A randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58 050 patients with suspected acute myocardial infarction. 345:669-685. 1995
Diagnosis of Chlamydia trachomatis genitourinary infection in women by ligase chain reaction assay of urine. 345:213-216. 1995
Dermatan sulphate in heparin-induced thrombocytopenia. 344:1295-1296. 1994
Randomised controlled trial of respiratory rehabilitation. 344:1394-1397. 1994
EFFECT OF CORONARY-ARTERY BYPASS GRAFT-SURGERY ON SURVIVAL - REPLY. 344:1224-1224. 1994
SALIVARY ANTIBODIES TO HELICOBACTER-PYLORI - SCREENING DYSPEPTIC PATIENTS BEFORE ENDOSCOPY. 344:1016-1017. 1994
Does immunological intercourse prevent pre-eclampsia?. 344:969-970. 1994
Effect of coronary artery bypass graft surgery on survival. 344:1222-1224. 1994
Is chest pain after sumatriptan oesophageal in origin?. 344:985-986. 1994
Salivary antibodies to Helicobacter pylori: screening dyspeptic patients before endoscopy. 344:1016-1017. 1994
Effect of coronary artery bypass graft surgery on survival: overview of 10-year results from randomised trials by the Coronary Artery Bypass Graft Surgery Trialists Collaboration. 344:563-570. 1994
Regular versus as-needed inhaled salbutamol in asthma control. 344:621-621. 1994
Asthma control. 344:344-344. 1994
Stress without distress: the intrauterine perspective. 344:73-74. 1994
GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Gruppo Italiano per lo Studio della Sopravvivenza nell'infarto Miocardico.. 343:1115-1122. 1994
Double-blind randomised trial of very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer. 343:886-889. 1994
Microfilaria, tolerance, and T cells. 343:868-869. 1994
Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. 343:311-322. 1994
Immunocytological test to detect adult carriers of (--SEA/) deletional α-thalassaemia. 342:1145-1147. 1993
Primidone and rapid cycling affective disorders. 342:925-925. 1993
RESPIRATORY DISEASE. 341:1377-1378. 1993
ACE inhibitors for myocardial infarction and unstable angina. 341:829-829. 1993
How much ethics is needed to make a good doctor?. 341:498-499. 1993
Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions. 340:1173-1178. 1992
How safe is BCG vaccination in children born to HIV-positive mothers?. 340:434-435. 1992
Transmission of hepatitis C with pasteurised factor VIII. 340:305-306. 1992
Aortic stenosis and bleeding gastrointestinal angiodysplasia: is acquired von Willebrand's disease the link?. 340:35-37. 1992
Central-nervous-system dysfunction after warm or hypothermic cardiopulmonary bypass. 339:1383-1384. 1992
ISIS-3: a randomised comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41 299 cases of suspected acute myocardial infarction. 339:753-770. 1992
Voluntary dehydration and heat intolerance in cystic fibrosis. 339:696-699. 1992
Second chance for the adrenal medulla transplant. 339:431-431. 1992
Recombinant factor VIII concentrate. 339:61-62. 1992
Dose reduction of beta-agonists in asthma. 338:1331-1332. 1991
Iron in neuroleptic malignant syndrome. 338:820-821. 1991
Serum iron and neuroleptic malignant syndrome. 338:149-151. 1991
Cyclophosphamide and plasma exchange in multiple sclerosis. 337:1540-1541. 1991
Effects of occupational therapy home service on patients with rheumatoid arthritis. 337:1453-1456. 1991
β2-agonists. 337:426-427. 1991
Ferioterol and fatal asthma. 337:186-187. 1991
Inhibition of Helicobacter pylori by acetohydroxamic acid. 336:1584-1585. 1990
Regular inhaled beta-agonist treatment in bronchial asthma. 336:1391-1396. 1990
MEDICAL SCIENCE GISSI-2: A factorial randomised trial of alteplase versus streptokinase and heparin versus no heparin among 12 490 patients with acute myocardial infarction. 336:65-71. 1990
Low-dose cyclosporin versus placebo in patients with rheumatoid arthritis. 335:1051-1055. 1990
Field trial of oral cholera vaccines in Bangladesh: results from three-year follow-up. 335:270-273. 1990
Fenoterol and fatal asthma. 335:45-46. 1990
COMPARISON OF DAILY AND TWICE-WEEKLY REGIMENS TO TREAT PULMONARY TUBERCULOSIS. 334:1173-1176. 1989
FENOTEROL AND FATAL ASTHMA. 334:45-45. 1989
CHRONIC COUGH: EOSINOPHILIC BRONCHITIS WITHOUT ASTHMA. 333:1346-1348. 1989
THE CANADIAN AMERICAN TICLOPIDINE STUDY (CATS) IN THROMBOEMBOLIC STROKE. 333:1215-1220. 1989
FENOTEROL AND FATAL ASTHMA. 333:1070-1071. 1989
SUCCESSFUL USE OF RECOMBINANT FACTOR VIIa IN PATIENT WITH SEVERE HAEMOPHILIA A DURING SYNOVECTOMY. 332:1193-1193. 1988
DEVELOPMENT OF ANTI-IDIOTYPIC ANTIBODIES AGAINST TUMOUR ANTIGENS AND AUTOANTIGENS IN OVARIAN CANCER PATIENTS TREATED INTRAPERITONEALLY WITH MOUSE MONOCLONAL ANTIBODIES. 332:894-897. 1988
HOSPITAL ADMINISTRATOR'S PARADOX. 332:1026-1026. 1988
GALLSTONE LITHOTRIPSY. 332:457-458. 1988
H2-RECEPTOR ANTAGONIST NON-RESPONDERS. 332:275-275. 1988
RANDOMISED COMPARISON OF TWO INTENSITIES OF ORAL ANTICOAGULANT THERAPY AFTER TISSUE HEART VALVE REPLACEMENT. 331:1242-1245. 1988
EFFECT OF INTRAVENOUS NITRATES ON MORTALITY IN ACUTE MYOCARDIAL-INFARCTION - AN OVERVIEW OF THE RANDOMIZED TRIALS. 1:1088-1092. 1988
SCREENING FOR INHERITED METABOLIC DISEASES IN ADULTS WITH NEUROLOGICAL DISEASE. 1:1101-1101. 1988
EFFECT OF INTRAVENOUS NITRATES ON MORTALITY IN ACUTE MYOCARDIAL INFARCTION: AN OVERVIEW OF THE RANDOMISED TRIALS. 331:1088-1092. 1988
USE OF OXYGEN THERAPY FOR ADULT PATIENTS OUTSIDE THE CRITICAL CARE AREAS OF A UNIVERSITY HOSPITAL. 331:981-983. 1988
CADMIUM FUME INHALATION AND EMPHYSEMA. 331:663-667. 1988
CHARGES FOR PREVENTIVE SERVICES. 331:245-245. 1988
HLA-DQ BETA-CHAIN POLYMORPHISM IN HLA-DR4 HAPLOTYPES ASSOCIATED WITH RHEUMATOID ARTHRITIS. 330:1118-1120. 1987
HEPATITIS B VACCINE AND HEALTH WORKERS' COMPENSATION CLAIMS. 330:913-914. 1987
POSSIBLE MECHANISM FOR CEREBRAL OEDEMA IN DIABETIC KETOACIDOSIS. 330:306-308. 1987
DNA DIAGNOSTIC LABORATORIES. 329:1434-1434. 1987
FALSE NEGATIVE RESULT BY THE WELLCOZYME ANTI-HIV ASSAY IN TESTING AN HIV POSITIVE HAEMOPHILIAC. 329:1200-1201. 1987
PROSTAGLANDINS FOR PEPTIC ULCER DISEASE. 329:1262-1262. 1987
CHORIONIC VILLUS SAMPLING FOLLOWED BY GENETIC AMNIOCENTESIS AND SEPTIC SHOCK. 329:867-868. 1987
OESTROGEN MODULATORS AND CLEAR CELL CARCINOMA OF VAGINA. 329:913-913. 1987
DOUBLE-BLIND RANDOMISED TRIAL OF ORG 10172 LOW-MOLECULAR-WEIGHT HEPARINOID IN PREVENTION OF DEEP-VEIN THROMBOSIS IN THROMBOTIC STROKE. 329:523-526. 1987
SIMULATED CARDIAC ARRESTS FOR MONITORING QUALITY OF IN-HOSPITAL RESUSCITATION. 328:618-620. 1986
UNEXPECTED MOBILISATION OF LEAD DURING CISPLATIN CHEMOTHERAPY. 328:249-250. 1986
SINGLE-PATIENT RANDOMISED CLINICAL TRIAL Use in Determining Optimum Treatment for Patient with Inflammation of Kock Continent Ileostomy Reservoir. 327:726-728. 1986
CONDUCTION BLOCK IN EARLY GUILLAIN-BARRE SYNDROME. 327:332-332. 1986
TAMOXIFEN PROPHYLAXIS. 327:263-265. 1986
PSYCHOTIC SYMPTOMS IN VOLUNTEERS SERVING OVERSEAS. 326:37-37. 1985
CHORIONIC VILLUS SAMPLING. 325:1269-1270. 1985
NOCTURNAL DOSES OF H2 RECEPTOR ANTAGONISTS FOR DUODENAL ULCER. 325:647-648. 1985
ACUTE VINCRISTINE NEUROTOXICITY. 325:346-346. 1985
ANGIOIMMUNOBLASTIC LYMPHADENOPATHY ASSOCIATED WITH RESERPINE. 324:820-821. 1984
WRIGHT'S b DETERMINANT, MONOCLONAL ANTIBODIES, AND PLASMODIUM FALCIPARUM MEROZOITE INVASION. 324:934-935. 1984
RANITIDINE 150 mg TWICE DAILY VS 300 mg NIGHTLY IN TREATMENT OF DUODENAL ULCERS. 324:274-276. 1984
POST-PARTUM HAEMOLYTIC URAEMIC SYNDROME AND VEROTOXIN-PRODUCING ESCHERICHIA COLI. 323:511-511. 1984
CYTOGENETICS IN THE EVALUATION OF PERINATAL DEATH. 1:630-631. 1984
INGESTION OF EGG RAISES PLASMA LOW-DENSITY LIPOPROTEINS IN FREE-LIVING SUBJECTS. 1:647-649. 1984
H2-BLOCKERS: NIGHT-TIME ONLY. 322:1371-1371. 1983
ENHANCEMENT OF HUMAN IMPLANTATION BY EXOGENOUS CHORIONIC GONADOTROPIN. 322:1191-1191. 1983
RENAL DYSFUNCTION IN CADMIUM SMELTERS: RELATION TO IN-VIVO LIVER AND KIDNEY CADMIUM CONCENTRATIONS. 321:1185-1187. 1983
BLEEDING AND DIVERTICULAR DISEASE. 321:830-830. 1983
PEPPERMINT OIL TO REDUCE COLONIC SPASM DURING ENDOSCOPY. 320:989-989. 1982
BRAIN TYPE CPK-BB AND CEREBRAL ISCHAEMIA AFTER SUBARACHNOID HAEMORRHAGE. 320:662-663. 1982
ANGIODYSPLASIA OF THE COLON. 320:16-19. 1982
INTRAGASTRIC ACIDITY, BACTERIA, NITRITE, AND N-NITROSO COMPOUNDS BEFORE, DURING, AND AFTER CIMETIDINE TREATMENT. 319:1091-1095. 1982
ANGIODYSPLASIA. 318:1340-1340. 1981
EVALUATING NEONATAL INTENSIVE CARE. 318:1052-1052. 1981
ETOPOSIDE: A NEW ANTI-CANCER AGENT. 318:912-915. 1981
ATENOLOL, HEPARIN AND THE INTERMEDIATE CORONARY SYNDROME. 318:46-46. 1981
ACETAZOLAMIDE IN THE MOUNTAINS. 317:552-553. 1981
DETECTION OF LEUCOCYTES IN PERITONEAL EFFLUENT BY TEST STRIP. 317:437-438. 1981
EVALUATING NEONATAL INTENSIVE-CARE. 2:1052-1052. 1981
CEREBRAL ŒDEMA IN FATAL MENINGOCOCCÆMIA. 316:967-969. 1980
Cerebral oedema in fatal meningococcaemia.. 2:967-969. 1980
MATERNAL HYPERPROLINÆMIA. 316:981-982. 1980
ŒSTROGEN USE AND SURVIVAL IN ENDOMETRIAL CANCER. 316:961-964. 1980
EARLY INTRAVENOUS ATENOLOL TREATMENT IN SUSPECTED ACUTE MYOCARDIAL INFARCTION. 316:273-276. 1980
SMALL-CELL LUNG CANCER. 315:252-252. 1980
CAPTOPRIL-ASSOCIATED AGRANULOCYTOSIS. 315:150-150. 1980
MATERNAL HYPERPROLINEMIA. 2:982-983. 1980
WORK-SITE TREATMENT OF HYPERTENSION BY SPECIALLY TRAINED NURSES. 314:1175-1178. 1979
EFFECT OF ATENOLOL ON RECOVERY OF THE ELECTROCARDIOGRAPHIC SIGNS OF MYOCARDIAL INFARCTION. 314:868-869. 1979
ISCHqMIC HEART-DISEASE AND GARLIC. 314:104-105. 1979
CADMIUM IN SHIPHAM. 313:551-551. 1979
MISDIAGNOSES OF ENDOGENOUS DEPRESSION WITH RESEARCH DIAGNOSTIC CRITERIA. 313:267-267. 1979
CRITICAL CONCENTRATION OF CADMIUM IN RENAL CORTEX AND URINE. 313:221-221. 1979
INSOMNIA, SEDATION, AND HIGH ALTITUDE CEREBRAL $OElig;DEMA. 313:165-165. 1979
MIS-DIAGNOSES OF ENDOGENOUS-DEPRESSION WITH RESEARCH DIAGNOSTIC CRITERIA. 1:267-267. 1979
USE OF CHRONIC CEREBELLAR STIMULATION FOR DISORDERS OF DISINHIBITION. 311:595-600. 1978
PLATELET AGGREGATION INDUCED BY SWINE INFLUENZA VACCINE. 311:277-278. 1978
ARTIFICIAL SWEETENERS AND HUMAN BLADDER CANCER. 310:578-581. 1977
ESKIMOS AND MULTIPLE SCLEROSIS. 309:1370-1370. 1977
MULTIPLE SCLEROSIS AND DOGS. 309:487-488. 1977
INFECTION ACQUIRED IN THE PATHOLOGY LABORATORY. 308:1406-1407. 1976
RICKETTSIA-LIKE BODIES AND SPLENITIS IN KAWASAKI DISEASE. 308:1254-1255. 1976
IMPROVEMENT OF MEDICATION COMPLIANCE IN UNCONTROLLED HYPERTENSION. 307:1265-1268. 1976
MINERAL-OIL CANCERS. 307:1082-1082. 1976
TERMINAL TRANSFERASE IN HUMAN BONE-MARROW LYMPHOCYTES. 307:508-509. 1976
HEALING OF GASTRIC ULCER DURING TREATMENT WITH CIMETIDINE. 307:337-339. 1976
T AND B LYMPHOCYTES IN BREAST CANCER STAGE RELATIONSHIP AND ABROGATION OF T-LYMPHOCYTE DEPRESSION BY ENZYME TREATMENT IN VITRO. 307:330-333. 1976
RANDOMISED CLINICAL TRIAL OF STRATEGIES FOR IMPROVING MEDICATION COMPLIANCE IN PRIMARY HYPERTENSION. 305:1205-1207. 1975
EPIDEMIC OF AORTIC ANEURYSM?. 304:1575-1575. 1974
MYOPATHIES: THE NEUROGENIC HYPOTHESIS. 304:42-42. 1974
MOTONEURONE DISEASE AND AGEING. 302:1477-1480. 1973
RELEVANCE OF PREOPERATIVE AND POSTOPERATIVE BLOOD TESTS TO POSTOPERATIVE LEG-VEIN THROMBOSIS. 302:805-809. 1973
MEASUREMENT OF WHOLE-BODY NITROGEN BY NEUTRON-ACTIVATION ANALYSIS. 302:395-399. 1973
THE DOUBLE CRUSH IN NERVE-ENTRAPMENT SYNDROMES. 302:359-362. 1973
AUSTRALIAN MULTICENTRE TRIAL OF STREPTOKINASE IN ACUTE MYOCARDIAL INFARCTION. 301:57-60. 1973
FETAL/MATERNAL INCOMPATIBILITY. 300:1095-1096. 1972
DEXAMETHASONE TREATMENT IN HERPES-SIMPLEX ENCEPHALITIS. 297:861-861. 1971
" SICK " MOTONEURONES. 297:321-325. 1971
DEXAMETHASONE TREATMENT IN HERPES-SIMPLEX ENCEPHALITIS. 297:290-291. 1971
ALPHA RHYTHM: AN ARTEFACT?. 295:1109-1110. 1970
MUSCULAR DYSTROPHY: MYOPATHY OR NEUROPATHY?. 295:1119-1119. 1970
ELECTROENCEPHALOGRAPHY IN DIAGNOSIS OF HERPES-SIMPLEX ENCEPHALITIS. 295:650-652. 1970
THE RESPONSIBILITIES OF THE CONSULTANT GRADE. 294:689-689. 1969
METHOHEXITONE AND THE E.E.G.. 294:110-110. 1969
CLINICAL HÆMATOLOGY. 293:941-942. 1969
CHANGES IN PLATELET BEHAVIOUR DURING ARVIN THERAPY. 293:644-647. 1969
HÆMODIALYSIS IN THE HOME. 293:614-617. 1969
HÆMOLYTIC-URÆMIC SYNDROME. 292:1394-1394. 1968
CEPHALORIDINE TOXICITY. 291:47-48. 1968
MICROANGIOPATHIC HÆMOLYTIC ANÆMIA. 291:90-90. 1968
EXPERIMENTAL PRODUCTION OF MICROANGIOPATHIC HÆMOLYTIC ANÆMIA IN VIVO. 290:1121-1123. 1967
RED-BLOOD-CELL FRAGMENTATION IN MICROANGIOPATHIC HÆMOLYTIC ANÆMIA: IN-VITRO STUDIES. 290:1123-1125. 1967
RESOLUTION OF ACUTE MASSIVE PULMONARY EMBOLISM AFTER PULMONARY ARTERIAL INFUSION OF STREPTOKINASE. 290:593-597. 1967
INTRAVASCULAR HÆMOLYSIS AND DISSEMINATED INTRAVASCULAR COAGULATION. 289:601-602. 1967
THE EMPHYSEMATOUS AND BRONCHIAL TYPES OF CHRONIC AIRWAYS OBSTRUCTION. 287:830-835. 1966
PORPHYRIA. 278:213-214. 1961
HÆMOGLOBIN-H TRAIT IN A NEPALESE GURKHA WOMAN. 271:192-194. 1958

The Lancet Journal

Overview

publication venue for

has subject area

Identity

International Standard Serial Number (ISSN)

Electronic International Standard Serial Number (EISSN)